2,840 results on '"Mielke, Michelle."'
Search Results
152. Sex Differences in Alzheimer’s Disease
153. Cohort study examining associations between ceramide levels and risk of multimorbidity among persons participating in the Mayo Clinic Biobank
154. Changes in Loneliness, BDNF, and Biological Aging Predict Trajectories in a Blood-Based Epigenetic Measure of Cortical Aging: A Study of Older Black Americans
155. Accumulation of pTau231 at the Postsynaptic Density in Early Alzheimer’s Disease
156. Association of Hypertensive Disorders of Pregnancy With Cognition in Later Life
157. Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum
158. Pregnancy history and blood-borne microvesicles in middle aged women with and without coronary artery calcification
159. Peripheral sphingolipids are associated with variation in white matter microstructure in older adults
160. Plasma sphingolipid changes with autopsy-confirmed Lewy body or Alzheimer's pathology
161. Levodopa-induced dyskinesia in Parkinson disease: A population-based cohort study
162. Sex-specific norms for verbal memory tests may improve diagnostic accuracy of amnestic MCI
163. Elevated Plasma Ceramides Are Associated With Higher White Matter Hyperintensity Volume—Brief Report
164. Cardiometabolic Health and Longitudinal Progression of White Matter Hyperintensity: The Mayo Clinic Study of Aging
165. Quantity and quality of mental activities and the risk of incident mild cognitive impairment
166. Association Between Critical Care Admissions and Cognitive Trajectories in Older Adults*
167. Plasma and CSF neurofilament light: Relation to longitudinal neuroimaging and cognitive measures
168. Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults
169. Physical Exercise, APOE E4 Genotype And Cognitive Trajectories: The Mayo Clinic Study Of Aging: 1785 May 30 4:00 PM - 4:15 PM
170. Functional Activity and Neuropsychiatric Symptoms in Normal Aging and Mild Cognitive Impairment: The Mayo Clinic Study of Aging
171. Early temporal characteristics of elderly patient cognitive impairment in electronic health records
172. Cortical β-amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging
173. Genetic risk scores enhance the diagnostic value of plasma biomarkers of brain amyloidosis.
174. Risk of dementia and psychiatric or sleep disorders after diagnosis of adrenal adenomas: a population-based cohort study.
175. Abstract P501: Midlife and Late-Life Non-Alcoholic Fatty Liver Disease and Incident Dementia: The Atherosclerosis Risk in Communities (ARIC) Study
176. Direct and Indirect Effects of Socioeconomic Status and Discrimination on Subjective Cognitive Decline: A Longitudinal Study of African American Women
177. Predicting amyloid PET and tau PET stages with plasma biomarkers
178. Associations of Neurodegeneration Biomarkers in Cerebrospinal Fluid with Markers of Alzheimer’s Disease and Vascular Pathology
179. Dual cognitive and mobility impairments and future dementia ‐ Setting a research agenda
180. Plasma amyloid beta 40/42, phosphorylated tau 181, and neurofilament light are associated with cognitive impairment and neuropathological changes among World Trade Center responders: A prospective cohort study of exposures and cognitive aging at midlife
181. Mayo‐PACC: A parsimonious preclinical Alzheimer's disease cognitive composite comprised of public‐domain measures to facilitate clinical translation
182. Convergent and criterion validity of a computer adaptive self‐administered word list memory test and the Mayo Test Drive composite: correlations with traditional measures and group difference by PET imaging biomarker status in persons without dementia.
183. Comparing cerebrovascular disease diffusion MRI markers using post‐mortem and longitudinal imaging data
184. Amyloid independent pathways have an impact on longitudinal tau deposition
185. Analytical Validation of the Quanterix Neurofilament Light Chain (NfL) Advantage Assay in Plasma
186. White matter health in the context of Alzheimer’s disease pathophysiology
187. Diagnostic accuracy of the Stricker Learning Span and Mayo Test Drive Composite for amnestic Mild Cognitive Impairment.
188. Gait Correlates of Cognitive Function and Future Decline
189. An examination of the usability of the Mayo Test Drive remote cognitive testing platform in older adults with and without cognitive impairment
190. Plasma Biomarkers of Amyloid and Neurodegeneration predictive of Neuropathologic Scales of Cerebrovascular Disease
191. Interpreting blood‐based biomarker results in heterogeneous populations with multiple co‐morbidities
192. Paroxetine and fluconazole therapy for HIV-associated neurocognitive impairment: results from a double-blind, placebo-controlled trial
193. Dr. Kodishala et al reply
194. Trajectories of metabolic parameters after bilateral oophorectomy in premenopausal women
195. RELATIONSHIPS OF CEREBRAL PERFUSION WITH GAIT SPEED ACROSS AGE AND SYSTOLIC BLOOD PRESSURE LEVELS
196. ASSOCIATIONS BETWEEN PRESCRIPTION OPIOID AVAILABILITY AND LONGITUDINAL CHANGES IN COGNITION IN OLDER ADULTS
197. Stricker Learning Span criterion validity: a remote self-administered multi-device compatible digital word list memory measure shows similar ability to differentiate amyloid and tau PET-defined biomarker groups as in-person Auditory Verbal Learning Test
198. Association of Premenopausal Bilateral Oophorectomy With Parkinsonism and Parkinson Disease
199. Cancer and Vascular Comorbidity Effects on Dementia Risk and Neuropathology in the Oldest-Old
200. Global neuropathologic severity of Alzheimer’s disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.